Shilpa Medicare Gets SEC Approval For Oeris™ Injection Lasting Up To 120 Hours

Market snapshot: Shilpa Medicare Limited has received final approval from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) for the grant of marketing authorization for Oeris™ (Ondansetron Extended-Release Injection, 100 mg/mL). As the world's first once-weekly extended-release injectable ondansetron formulation, the drug provides sustained antiemetic action for up to 120 hours (5 days) from a single administration. The company has finalized plans for its commercial launch in India and holds domestic patent protection for the novel therapeutic until 2039.

Data Snapshot

• Approved dosage strength concentration of Oeris™ Extended-Release Injection
• Sustained antiemetic protection duration post a single Oeris™ administration
• Patent protection horizon for Oeris™ in India
• Consolidated Q1 FY27 revenue from operations reported by Shilpa Medicare
• Consolidated Q1 FY27 net profit representing a 115% year-on-year increase

What's Changed

• Consolidated revenue from operations grew to ₹466 crore in Q1 FY27 from ₹321.5 crore in Q1 FY26 (derived: ≈45% YoY growth).
• Consolidated net profit increased to ₹101 crore in Q1 FY27 from ₹47 crore in Q1 FY26 (derived: ≈115% YoY growth).
• Consolidated EBITDA rose to ₹136.2 crore in Q1 FY27 from ₹91.6 crore in Q1 FY26 (derived: ≈48.6% YoY growth).

Key Takeaways

• Shilpa Medicare has secured Subject Expert Committee (SEC) final approval for marketing authorization of Oeris™ (100 mg/mL) in India.
• The drug represents the world’s first once-weekly extended-release ondansetron injection, offering up to 120 hours of antiemetic protection.
• Oeris™ is designed to eliminate the clinical need for multiple daily doses or oral therapies in oncology supportive care.
• With domestic patent protection valid until 2039, Shilpa Medicare establishes a long-term commercial exclusive moat in India.

SAHI Perspective

The SEC-CDSCO regulatory clearance for Oeris™ is a vital validation of Shilpa Medicare’s R&D capabilities in high-value Novel Drug Delivery Systems (NDDS). Moving from conventional, frequent daily dosing of ondansetron to a single weekly injection greatly improves patient compliance and clinician workflow in chemotherapy-induced nausea and vomiting (CINV) management. This first-of-its-kind globally approved formulation, protected by Indian patents until 2039, gives Shilpa Medicare a powerful specialty therapeutic moat in India and creates a solid foundation for upcoming international registrations via the US FDA 505(b)(2) pathway.

Market Implications

The commercialization of Oeris™ is set to strengthen Shilpa Medicare's high-margin formulations business, which registered exceptional growth in Q1 FY27. Generating exclusive domestic revenues on a patented, first-in-class oncology asset will likely expand operating EBITDA margins. Furthermore, successful domestic deployment will enhance the company’s CDMO standing with global innovators looking to partner in complex injectables.

Trading Signals

Market Bias: Bullish

The approval of Oeris™ provides a patented, high-margin domestic portfolio addition with zero direct competitors for up to 120 hours of therapeutic action. This novel drug launch is backed by solid corporate financials, as consolidated net profit jumped 115% YoY to ₹101 crore in Q1 FY27.

Overweight: Pharmaceuticals, Specialty Generics, Oncology Supportive Care

Trigger Factors:

• Initial commercial rollout and volume adoption across oncology hospitals in India
• Licensing agreement partnerships and filing progress for Oeris™ in the United States and EU
• Subsequent expansion in consolidated formulation margins over the next 2-4 quarters

Time Horizon: Medium-term (3-12 months)

Industry Context

Chemotherapy-induced nausea and vomiting (CINV) prophylaxis is standard supportive care in global oncology. Antiemetics like ondansetron have historically faced compliance hurdles due to the need for multiple daily oral or intravenous doses post-chemotherapy. Sustained-release formulations that span both acute and delayed CINV phases (covering up to 5 days) represent a major therapeutic leap forward, offering significant market capture opportunities for early innovators.

Key Risks to Watch

• Physician and clinical adoption rates of a premium novel injection over cheap, generic short-acting antiemetics.
• Execution risks on upcoming global regulatory filings across regulated markets.
• Unfavorable outcomes or financial spillovers from the Corporate Insolvency Resolution Process (CIRP) admitted against wholly owned subsidiary FTF Pharma Private Limited on September 9, 2026.

Recent Developments

On September 11, 2026, Shilpa Medicare announced that the CDSCO Subject Expert Committee (SEC) approved Oeris™ for marketing authorization. This follows positive Q1 FY27 financial results declared on August 5, 2026, where consolidated operations revenue rose 45% YoY to ₹466 crore. In other recent corporate events, the NCLT Ahmedabad bench admitted an insolvency petition under Section 9 of the IBC against its wholly owned subsidiary FTF Pharma Private Limited on September 9, 2026. Additionally, in late June 2026, subsidiary Shilpa Biologicals commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing site in Dharwad, Karnataka.

Closing Insight

Shilpa Medicare's transition from a generic active pharmaceutical ingredient (API) manufacturer to an innovation-driven specialty formulations player reaches an inflection point with the Oeris™ approval. By resolving real-world patient and clinical pain points with a world-first patented product, the company establishes a robust domestic platform that can be scaled internationally, driving premium valuation opportunities.

High Performance Trading with SAHI.